Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EmPAH: Empagliflozin in Pulmonary Arterial Hypertension
2024-517009-99-00Phase 2Suspended
- Sponsor
- Philipps-Universität Marburg
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in pulmonary arterial hypertension (PAH) comparing Empagliflozin arm with Placebo arm (2 arms). Primary endpoint: Primary: Change in S´/RAAi ratio. Started Dec 2025; status: suspended.
02
Drugs
empagliflozin
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on 2024-517009-99-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517009-99-00.